At 7.4% CAGR, the Europe Intravenous Immunoglobulin Market is projected to be worth US$ 5,363.10 million by 2028, says Business Market Insights 

According to Business Market Insights' research, the Europe intravenous immunoglobulin market was valued at US$ 3,495.39 million in 2022 and is expected to reach US$ 5,363.10 million by 2028, registering a CAGR of 7.4% from 2022 to 2028. Increasing geriatric population and rising prevalence of immunodeficiency diseases are the critical factors attributed to the market expansion. 

As per the Eurostat, in 2019, there were around 90.4 million older people (aged 65 years or above) living in the EU-27. As per the United Nations Population Division, World Population Prospects 2019, Asian and European countries have some of the world's oldest populations aged 65 and more. Japan being at top with 28%, followed by Italy at 23%. Further, Finland, Portugal, and Greece are among the top five countries with aged population under 22%. Many of the patients treated with IVIG are above the age of 60 years. With aging, the ability to produce T-cells to fight diseases gets significantly reduced. Thus, an older person's body is easily prone to several infections and diseases, which increases the demand for immune therapies that involve use of IVIg. Thus, the increase in geriatric population across the region is bolstering the intravenous immunoglobulin market. 

On the contrary, adverse effects of immunoglobulin therapy hurdles the growth of Europe intravenous immunoglobulin market. 

Based on type, the Europe intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment held 28.8% market share in 2022, amassing US$ 1,005.64 million. It is projected to garner US$ 1,532.26 million by 2028 to expand at 7.3% CAGR during 2022-2028. 

Based on application, the Europe intravenous immunoglobulin market is segmented hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment held 21.6% market share in 2022, amassing US$ 755.53 million. It is projected to garner US$ 1,196.92 million by 2028 to expand at 8.0% CAGR during 2022-2028.

Based on distribution channel, the Europe intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment held 55.8% market share in 2022, amassing US$ 1,949.51 million. It is projected to garner US$ 2,968.11 million by 2028 to expand at 7.3% CAGR during 2022-2028.

Based on end user, the Europe intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The beverages segment held 47.6% market share in 2022, amassing US$ 1,662.23 million. It is projected to garner US$ 2,514.16 million by 2028 to expand at 7.1% CAGR during 2022-2028.

Based on country, the Europe intravenous immunoglobulin market is segmented into Germany, UK, France, Italy, Spain, and Rest of Europe. Our regional analysis states that Germany captured 26.6% market share in 2022. It was assessed at US$ 929.22 million in 2022 and is likely to hit US$ 1,440.72 million by 2028, exhibiting a CAGR of 7.6% during the forecast period. 

Key players dominating the Europe intravenous immunoglobulin market are ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited among others. 

In 2022, BPL and Atlantic Research Group entered into long-term collaboration. This agreement establishes ARG as BPL's preferred contract research organization (CRO) for conducting clinical research trials and providing supportive services for the company's global new product development programs. The agreement builds on BPL and ARG's previous successful collaboration on clinical trial programs. 

In 2021, Grifols began a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug 

Based on the Grifols immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease. 

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com